Immune-mediated adverse events associated with the checkpoint inhibitor therapy

Vitaly B. Kaliberdenko , Elvina R. Kuliyeva , Victoria S. Beter , Emiliya R. Zagidullina , Tatyana S. Pronkina , Valeria A. Kushner , Victoria V. Taran

For citation:

Abstract

Objective: to evaluate immune-related adverse events (irAE) during therapy with immune checkpoint inhibitors. The literary review is based on the analysis of scientific publications hosted on the following databases: CyberLeninka, Web of Science, PubMed, Embase, eLIBRARY, CNKI and MEDLINE. The search was carried out using the following keywords: “immune checkpoints”, “immune-mediated adverse reactions”, “antitumor therapy”, “immune system”, “side effects”, “immune checkpoint inhibitors”. Immune checkpoint inhibitors (ICTs) have become a revolutionary breakthrough in oncology due to their ability to block CTLA-4 and PD-1/PD-L1 signaling pathways, activating lymphocytes and enhancing antitumor immunity. This significantly improved the prognosis of cancer. However, the mechanism of action of ICT, aimed at inhibiting immune checkpoints, can disrupt the regulation of the immune response, leading to the development of irAE. Hormonal drugs, immunosuppressants, and cytokine antagonists are the main agents for the treatment of irAE, but they can suppress antitumor immunity. The issues of mechanisms, biomarkers of early diagnosis and individualized treatment of complications remain unresolved. It is assumed that the wider use of immunotherapy and an in-depth study of the mechanisms of action of immune checkpoint inhibitors, as well as irAE, will solve these problems and optimize the results of treatment of cancer patients. In this regard, this topic is of considerable interest to practicing physicians.

Keywords: checkpoint inhibitor therapy, adverse events.

References

1. Common terminology criteria for adverse events (CTCAE) V5. URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 2. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29-39. DOI: 10.1016/j.intimp.2018.06.001

3. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535. DOI: 10.1001/jamanetworkopen.2019.2535

4. Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019;145:639-48. DOI: 10.1002/ijc.32132

5. Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26:3009-25. DOI: 10.2174/09298673 24666170804143706

6. Wang J, Yang T, Xu J. Therapeutic development of immune checkpoint inhibitors. Adv Exp Med Biol. 2020;1248:619-49. DOI: 10.1007/978-981-15-3266-5_23

7. Willsmore ZN, Coumbe B, Crescioli S, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021;51:544-56. DOI: 10.1002/eji.202048747

8. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275-87. DOI: 10.1038/nrc.2016.36

9. Cuyas E, Verdura S, Martin-Castillo B, et al. Tumor cell-intrinsic immunometabolism and precision nutrition in cancer immunotherapy. Cancers (Basel). 2020;12(7):1757. DOI: 10.3390/cancers12071757

10. Lim S, Phillips JB, Madeira DSL, et al. Interplay between immune checkpoint proteins and cellular metabolism. Cancer Res. 2017:77:1245-9. DOI: 10.1158/0008-5472.CAN-16-1647

11. Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14:45. DOI: 10.1186/s13045-021-01056-8

12. Barclay J, Creswell J, Leon J. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Arch Esp Urol. 2018;71:393-9.

13. Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23:39. DOI: 10.1208/s12248-021-00574-0

14. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350-5. DOI: 10.1126/science.aar4060

15. Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10. DOI: 10.1186/s12943-018-0928-4

16. Liao D, Wang M, Liao Y, et al. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol. 2019;10:609. DOI: 10.3389/fphar.2019.00609

17. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32-42. DOI: 10.1158/2326-6066.CIR-13-0013

18. Waight JD, Chand D, Dietrich S, et al. Selective FcgammaR Co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell. 2018;33:1033-47. DOI: 10.1016/j.ccell.2018.05.005

19. Qi Y, Chen L, Liu Q, et al. Research progress concerning dual blockade of lymphocyte-activation gene 3 and programmed death-1/programmed death-1 ligand-1 blockade in cancer immunotherapy: preclinical and clinical evidence of this potentially more effective immunotherapy strategy. Front Immunol. 2020;11:563258. DOI: 10.3389/ fimmu.2020.563258

20. Chocarro L, Blanco E, Zuazo M, et al. Understanding LAG-3 signaling. Int J Mol Sci. 2021;22(10):5282. DOI: 10.3390/ijms22105282

21. Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011;186:5173-83. DOI: 10.4049/jimmunol.1002050 22. Lythgoe MP, Liu D, Annels NE, et al. Gene of the month: lymphocyte-activation gene 3 (LAG-3). J Clin Pathol. 2021;74:543-7. DOI: 10.1136/jclinpath-2021-207517

23. Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14:147. DOI: 10.1186/s13045-021-01161-8

24. Xu F, Liu J, Liu D, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014;74:3418-28. DOI: 10.1158/0008-5472.CAN-13-2690

25. Kouo T, Huang L, Pucsek AB, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3:412-23. DOI: 10.1158/2326-6066.CIR-14-0150

26. Mao X, Ou MT, Karuppagounder SS, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353(6307):aah3374. DOI: 10.1126/science.aah3374

27. Kang CW, Dutta A, Chang LY, et al. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. Sci Rep. 2015;5:15659. DOI: 10.1038/srep15659

28. Rocha M, Correia DSJ, Salgado M, et al. Management of gastrointestinal toxicity from immune checkpoint inhibitor. GE Port J Gastroenterol. 2019;26:268-74. DOI: 10.1159/000494569

29. Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 2017;6:51-71. DOI: 10.2147/ITT.S141577

30. Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (dire) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019;7:165. DOI: 10.1186/s40425-019-0645-6

31. Duma N, Lambertini M. It is time to talk about fertility and immunotherapy. Oncologist. 2020;25:277-8. DOI: 10.1634/theoncologist.2019-0837

32. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19:82-92. DOI: 10.1007/s11102-015-0671-4

33. Andrade Vila JH, da Silva JP, Guilhen CJ, et al. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. Transplantation. 2008;86:369-70. DOI: 10.1097/TP.0b013e31817cf28a

34. Merlob P, Stahl B, Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol. 2009;28:105-8. DOI: 10.1016/j.reprotox.2009.02.007

35. Burotto M, Gormaz JG, Samtani S, et al. Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Semin Oncol. 2018;45:164-9. DOI: 10.1053/j.seminoncol.2018.03.003

36. Xu W, Moor RJ, Walpole ET, et al. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res. 2019;29:333-7. DOI: 10.1097/CMR.0000000000000586

37. Bucheit AD, Hardy JT, Szender JB, et al. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res. 2020;30:423-5. DOI: 10.1097/CMR.0000000000000657

38. Butterfield LH, Kaufman HL, Johnson DH. SITC’s Guide to Managing Immunotherapy Toxicity. 1st ed. New York: Springer Publishing Company, 2019. URL: https://scholar.google.com/scholar_lookup? title=SITC’s%20Guide%20to%20Managing%20Immunotherapy%20Toxicity,%201%20edn&publication_year=2019& 39. Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of Corticosteroid-Associated adverse events: a systematic literature review. Clin Ther. 2011;33:1413-32. DOI: 10.1016/j.clinthera.2011.09.009

40. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721-8. DOI: 10.1001/jamaoncol.2018.3923

For citation: Kaliberdenko V.B., Kuliyeva E.R., Beter V.S., Zagidullina E.R., Pronkina T.S., Kushner V.A., Taran V.V. Immune-mediated adverse events associated with the checkpoint inhibitor therapy. Clinical review for general practice. 2025; 6 (7): 25–30 (In Russ.). DOI: 10.47407/kr2025.6.7.00641

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice